These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7801144)
1. High-dose therapy and autografting with peripheral blood stem cells in malignant lymphoma: granulocyte-macrophage colony-stimulating factor for stem cell mobilization. Haas R; Hohaus S; Goldschmidt H; Möhle R; Witt B; Wannenmacher M; Hunstein W Semin Oncol; 1994 Dec; 21(6 Suppl 16):19-24. PubMed ID: 7801144 [No Abstract] [Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
3. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026 [TBL] [Abstract][Full Text] [Related]
4. Large volume leukapheresis following peripheral blood stem cell mobilization by cyclophosphamide and granulocyte-macrophage colony stimulating factor. Safran H; Caguioa P; Tansan S Prog Clin Biol Res; 1994; 389():639-42. PubMed ID: 7700930 [No Abstract] [Full Text] [Related]
5. A retrospective comparison of three different methods for mobilization of peripheral blood stem cells. Mangan KF; Mullaney MT; Klumpp TR; Goldberg SL; Macdonald JS Prog Clin Biol Res; 1994; 389():441-8. PubMed ID: 7535452 [No Abstract] [Full Text] [Related]
6. Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standard-dose chemotherapy in patients with malignancy. Kobayashi N; Kasai M; Masauzi N; Ogasawara M; Kiyama Y; Naohara T; Higa T; Hashino S; Tanaka J; Imamura M Jpn J Clin Oncol; 1995 Dec; 25(6):250-7. PubMed ID: 8523821 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma. Fay JW; Bernstein SH Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545 [TBL] [Abstract][Full Text] [Related]
8. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159 [TBL] [Abstract][Full Text] [Related]
9. Dose-intensified therapy combined with autologous blood stem cell support in patients with multiple myeloma. Serke S; Kirsch A; Huhn D Semin Oncol; 1994 Dec; 21(6 Suppl 16):29-32. PubMed ID: 7528448 [No Abstract] [Full Text] [Related]
10. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Rosenfeld CS; Bolwell B; LeFever A; Taylor R; List A; Fay J; Collins R; Andrews F; Pallansch P; Schuster MW; Resta D; Levitt D; Nemunaitis J Bone Marrow Transplant; 1996 Feb; 17(2):179-83. PubMed ID: 8640163 [TBL] [Abstract][Full Text] [Related]
11. Long-term cultures to evaluate engraftment potential of CD34+ cells from peripheral blood after mobilization by chemotherapy with and without GM-CSF. Benboubker L; Domenech J; Linassier C; Desbois I; Delain M; Lamagnere JP; Colombat P; Binet C Exp Hematol; 1995 Dec; 23(14):1568-73. PubMed ID: 8542948 [TBL] [Abstract][Full Text] [Related]
12. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
13. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784 [TBL] [Abstract][Full Text] [Related]
14. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Strodtbeck D; Bornhäuser M; Hänel M; Lerche L; Schaich M; Illmer T; Thiede C; Geissler G; Herbst R; Ehninger G; Platzbecker U Bone Marrow Transplant; 2005 Dec; 36(12):1083-8. PubMed ID: 16247435 [TBL] [Abstract][Full Text] [Related]
15. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression. Watanabe T; Dave B; Heimann DG; Lethaby E; Kessinger A; Talmadge JE Bone Marrow Transplant; 1997 Jun; 19(12):1175-81. PubMed ID: 9208110 [TBL] [Abstract][Full Text] [Related]